Harbour BioMed is a global biopharmaceutical company developing innovative therapeutics in the field of immuno-oncology and inflammatory diseases. The company's discovery and development programs are centered around its two patented transgenic mouse platforms generating fully human monoclonal antibodies.

The company is building its proprietary pipeline internally, through collaborations with co-development partners, as well as through select preclinical and clinical stage asset acquisitions. Harbour BioMed also licenses the platforms to companies and academic institutions through its Harbour Antibodies subsidiary.

Harbour BioMed has operation and an R&D site in Shanghai, China, business operations and innovation center including research laboratory in Boston, USA, and an antibody platform innovation center in Rotterdam, The Netherlands.